These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1698 related articles for article (PubMed ID: 27115376)

  • 1. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
    JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
    Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
    J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
    J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
    Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
    Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
    Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
    Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of HDM SLIT Tablet in Japanese Adults with Allergic Asthma.
    Tanaka A; Tohda Y; Okamiya K; Azuma R; Terada I; Adachi M
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):710-720.e14. PubMed ID: 31541768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
    Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
    Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SQ HDM SLIT-tablet (ALK) in treatment of asthma--post hoc results from a randomised trial.
    de Blay F; Kuna P; Prieto L; Ginko T; Seitzberg D; Riis B; Canonica GW
    Respir Med; 2014 Oct; 108(10):1430-7. PubMed ID: 25135744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
    Canonica GW; Virchow JC; Zieglmayer P; Ljørring C; Smith IM; Mosbech H
    Expert Rev Clin Immunol; 2016 Aug; 12(8):805-15. PubMed ID: 27322777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.
    Bernstein DI; Kleine-Tebbe J; Nelson HS; Bardelas JA; Sussman GL; Lu S; Rehm D; Svanholm Fogh B; Nolte H
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):105-110. PubMed ID: 29656145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study.
    Okamiya K; Sekino H; Azuma R; Kudo M; Sakaguchi M; Nemoto F; Muramatsu N; Maekawa Y; Tanaka A
    J Asthma; 2019 Dec; 56(12):1347-1355. PubMed ID: 30444150
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and Safety of House Dust Mite Sublingual Immunotherapy Tablet in Allergic Asthma: A Systematic Review of Randomized Controlled Trials.
    Wongsa C; Phinyo P; Sompornrattanaphan M; Krikeerati T; Lumkul L; Thongngarm T
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1342-1355.e24. PubMed ID: 35181547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
    Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
    J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis.
    Bergmann KC; Demoly P; Worm M; Fokkens WJ; Carrillo T; Tabar AI; Nguyen H; Montagut A; Zeldin RK
    J Allergy Clin Immunol; 2014 Jun; 133(6):1608-14.e6. PubMed ID: 24388010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.
    Devillier P; Fadel R; de Beaumont O
    Allergy; 2016 Feb; 71(2):249-57. PubMed ID: 26465232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.